Organoids and organs-on-a-chip as new approach methodologies at the convergence of cell biology and bioengineering.

Organoids and organs-on-a-chip are emerging as human tissue models that better recapitulate complex microenvironments, multi-organ interactions, and patient-specific biology than traditional preclinical systems.

• Why it matters: Drug development and clinical application pipelines still face long-standing gaps that traditional preclinical models cannot address, limiting how well human physiology and pathophysiology are represented.
• What they did: The work synthesizes advances in organoids, OOCs, and other bioengineered technologies for translational medicine, highlighting remaining challenges in reproducibility, validation, and regulatory acceptance.
• The result: It identifies opportunities at the intersection of synthetic biology, multi-omics, machine learning, and genetic engineering, positioning NAMs as foundational platforms for accelerating therapeutic discovery and enabling personalized medicine at scale.